Trial Profile
Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- 21 Jun 2012 New trial record